Abstract | UNLABELLED: BACKGROUND:
Gastroesophageal reflux disease ( GERD) is a common cause of chronic cough. Both acid and nonacid reflux is thought to play a role in the initiation of coughing and cough hypersensitivity. The GABAB receptor agonist lesogaberan was developed as a peripherally restricted anti-reflux therapy that reduces the frequency of transient lower esophageal sphincter relaxations (TLESR; the major cause of reflux) in animals and in patients with GERD. GABAB receptor agonists have also been shown to possess antitussive effects in patients and in animals independent of their effects on TLESR, suggesting that lesogaberan may be a promising treatment for chronic cough. METHODS: RESULTS: CONCLUSIONS: Together, the data suggest that lesogaberan and related GABAB receptor agonists may hold promise as safe and effective antitussive agents largely devoid of CNS side effects.
|
Authors | Brendan J Canning, Nanako Mori, Anders Lehmann |
Journal | Cough (London, England)
(Cough)
Vol. 8
Issue 1
Pg. 7
(Oct 01 2012)
ISSN: 1745-9974 [Electronic] England |
PMID | 23025757
(Publication Type: Journal Article)
|